June 2026– date –
-
Cosmos Health Subsidiary Cana Laboratories Acquires International Patent WO2025108566A1, Expanding Nanotechnology Investment to Accelerate Next-Gen Healthcare Product Development
Stock Titan USA Overview Cosmos Health announced that its wholly-owned subsidiary, Cana Laboratories S.A., has acquired international patent application WO2025108566A1 from Cloudpharm P.C., significantly expanding its nanotechnology inve... -
Invisible-Light Labs Secures €1.5M to Unveil NEMS-FTIR: A Picogram-Scale Revolution in Sub-Micron Analysis
BeBeez International オーストリア Overview Austrian DeepTech startup Invisible-Light Labs has successfully raised €1.5 million in pre-seed funding to accelerate the global commercialization of its groundbreaking sub-micron particle ident... -
Park Systems Invests in Advanced Nanoscale Metrology Portfolio to Drive Next-Gen 3D Packaging and Logic Research
PR Newswire USA Overview Park Systems, a global leader in AFM and nanoscale metrology, announced a strategic investment in its advanced metrology portfolio for 3D packaging and logic research. This initiative aims to accelerate the evolu... -
FAPI-46 Theranostic Agent Shows Promising Survival Benefits in Glioblastoma Peripheral Models, But Brain-Blood Barrier Permeation Remains a Challenge
Journal of Nuclear Medicine USA Overview A study on glioblastoma evaluated FAP inhibitor (FAPI)-46 as a theranostic agent targeting fibroblast activation protein (FAP). In vivo, diagnostic [68Ga]Ga-FAPI-46 demonstrated high tumor uptake,... -
Bioinspired Adiposomes Deliver Docetaxel to Lung, Multiple Myeloma, and Hepatocellular Carcinoma with Reduced Systemic Toxicity and Equivalent Efficacy
bioRxiv USA Overview Researchers have developed biocompatible adiposome nanoparticles for targeted delivery of the hydrophobic anticancer drug docetaxel (DTX), demonstrating significantly reduced systemic toxicity while maintaining equiv... -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
CombiCult® Screening Platform Establishes Feeder-Free Bioreactor Scalability for iPSC-Derived NK Cell Manufacturing
Frontiers (Preprint) Germany Overview This preprint reports research developing a feeder-free protocol for generating mature, functional iPSC-derived natural killer (iNK) cells using the high-throughput combinatorial screening platform C... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
Human Continuum Closes Over $5 Million in Seed Round Funding to Advance Exosome-Based Therapeutic Longevity Platform Development
GlobeNewswire (Human Continuum Inc.) USA Overview Human Continuum Inc. successfully completed a $5.13 million seed funding round to accelerate the development of its exosome-based therapeutic and diagnostic platform across longevity, ort... -
Novartis and Orionis Biosciences Enter Strategic Collaboration for Molecular Glue Discovery in Up to $1.4 Billion Deal
BioBucks Biotech BD&L Tracker USA Overview Novartis announced a strategic collaboration with Orionis Biosciences to leverage Orionis' AI-driven "Allo-Glue™" platform across multiple challenging therapeutic targets. The deal includes a $4...
